Trials / Unknown
UnknownNCT04850560
Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma
Sequential Low-dose Decitabine Therapy With Novel CAR-T Carrying PD-1/CD28 Chimeric Switch Receptor in Relapsed or Refractory B-cell Lymphoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of CD19 PD-1/CD28-CAR-T sequential low-dose decitabine in the treatment of relapse or refractory B cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine | CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine |
Timeline
- Start date
- 2021-05-18
- Primary completion
- 2022-05-01
- Completion
- 2024-05-01
- First posted
- 2021-04-20
- Last updated
- 2021-06-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04850560. Inclusion in this directory is not an endorsement.